Using blood markers for Alzheimer disease in clinical practice?
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Until recently, the notion of having blood markers of Alzheimer disease (AD) available for clinical use was more likely to be seen in an episode of a TV medical drama or a science fiction movie than in a peer-reviewed scientific journal. The search for biomarkers suffered from serious obstacles, including, but not limited to, inadequate diagnostic accuracy, and an inability to replicate findings across samples between laboratories or even within individual laboratories. However, the serious scientific world took notice when, in 2007, Ray et al.1 published a plasma-based screening tool that utilized advanced proteomic and bioinformatics methods to create a blood profile that was highly accurate in identifying persons with AD as well as those who were most likely to progress from mild cognitive impairment (MCI) to AD dementia. Enthusiasm diminished, …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer diseaseWilliam T. Hu, David M. Holtzman, Anne M. Fagan et al.Neurology, August 01, 2012 -
Article
Association of blood-based transcriptional risk scores with biomarkers for Alzheimer diseaseYoung Ho Park, Angela Hodges, Andrew Simmons et al.Neurology: Genetics, September 30, 2020 -
Article
Plasma tau in Alzheimer diseaseNiklas Mattsson, Henrik Zetterberg, Shorena Janelidze et al.Neurology, September 30, 2016 -
Article
Using AD biomarker research results for clinical careA survey of ADNI investigatorsMelanie B. Shulman, Kristin Harkins, Robert C. Green et al.Neurology, August 21, 2013